Infectious Diseases

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

Study explores how often children diagnosed with flu experience serious neuropsychiatric side effects

A Vanderbilt study is among the first to quantify how often children diagnosed with flu experience serious neuropsychiatric side effects.

A clinical trial supports approval of a new medication to treat moderate-to-severe asthma in children.

Study finds early RSV infection linked to significantly increased risk of asthma in children

A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.

Novel drugs have potential for treating tuberculosis

Drug-resistant tuberculosis is on the rise, and novel antibacterial drugs called SPTs have potential for treating the deadly lung infection.

From left, Xiang Ye, PhD, Suba Rajendren, PhD, Antiana Richardson, and John Karijolich, PhD, are studying how the cancer-causing virus KSHV commandeers host gene expression and regulatory machinery.

Study details RNA editing in virus-infected cancer cells

Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.

The study team includes, from left, Maribeth Nicholson, MD, MPH, Ben Spiller, PhD, Buddy Creech, MD, MPH, Borden Lacy, PhD, Eric Skaar, PhD, MPH, Isaac Thomsen, MD, MSCI, Ivelin Georgiev, PhD, and Danyvid Olivares-Villagomez, PhD.

NIH grant launches C. diff vaccine research initiative

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

1 2 3 4 5 6 10